- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04169152
CAES for Internal Hemorrhoids and Rectal Prolapse
December 20, 2019 updated by: Faming Zhang
Cap-assisted Endoscopic Sclerotherapy for Internal Hemorrhoids and Rectal Prolapse: a National Multi-centre Prospective Cohort Study
Cap-assisted endoscopic sclerotherapy (CAES) is a new interventional therapy for internal hemorrhoids and rectal prolapse under colonoscopy.
However, the long-term efficacy and safety of CAES in the treatment of internal hemorrhoids and rectal prolapse are still not clear due to the lack of large sample studies.
Therefore, a nationwide multi-center, large sample, prospective and cohort study was designed to evaluate the efficacy and safety of CAES in the treatment of internal hemorrhoids and rectal prolapse, to provide reliable evidence for popularization of this minimally invasive technology.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
CAES is an innovative endoscopic sclerotherapy procedure which is different from traditional method.
Firstly, the cap added to the front of colonoscope can fully expose the operating field.
Secondly, before or during the opportunity of CAES, endoscopist can perform endoscopic differentiation diagnosis (such as tumors, inflammatory bowel disease and others induced hematochezia), endoscopic therapy within lower-gut based on the same colon preparation, thus saving patients' medical cost, physical and mental pain.
The last but not least, specially designed length of endoscopic injection needle (eg.10-20 mm) was used in CAES could be helpful for accurately controlling the injection angle, direction, depth under direct vision and to avoid iatrogenic injury due to ectopic injection.The core value of CAES for internal hemorrhoids and rectal prolapse is to provide precise therapy, reduce the iatrogenic injuries, avoid pain during and after therapy.
Our pilot studies demonstrated that CAES based on long injection needle is an effective, safe, convenient operation technique.
100% of participants underwent CAES showed sustained clinical efficacy within the 3-month follow-up, with no severe or obvious complications related to CAES.
However, the long-term efficacy and safety of CAES in the treatment of internal hemorrhoids and rectal prolapse need to be confirmed by further large sample real world studies.
Study Type
Observational
Enrollment (Anticipated)
10000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Faming Zhang, MD,PhD
- Phone Number: 02558509884
- Email: fzhang@njmu.edu.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Grade I-III internal hemorrhoids and/or rectal prolapse
Description
Inclusion Criteria:
- Grade I-III internal hemorrhoids (with or without external hemorrhoids) or/and recal prolapse.
- Patients with bowel preparation.
Exclusion Criteria:
- History of anoscopic/endoscopic sclerotherapy.
- Acute thrombotic hemorrhoids or grade IV internal hemorrhoids.
- Anal stenosis, perianal and perirectal abscess, anal fissure, fistula, fecal incontinence and other severe complications (such as severe anal pain).
- Inflammatory bowel disease.
- Full-thickness rectal prolapse through the anus.
- Acute diarrhea in the past 24 hours.
- Hypertensive with uncontrolled blood pressure.
- Cerebrovascular accident.
- Blood coagulation dysfunction.
- Pregnant women.
- Mental disorders.
- Decompensated cirrhosis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Internal hemorrhoids and rectal prolapse
Participants were treated with Cap-assisted endoscopic sclerotherapy (CAES).
|
Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence rate
Time Frame: 1st week to 24th week
|
Recurrence defined as recurrent prolapse, bleeding and other symptoms such as anal pendant expansion, itching, dampness and others after CAES or seeking repeat CAES treatment, alternative non-surgical/surgical treatments for internal hemorrhoids or rectal prolapse (except medication treatment).
|
1st week to 24th week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement rate
Time Frame: 1st day, 1st week, 2nd week and 24th week
|
Bleeding, prolapse, and anal pain had resolved or remitted after CAES.
Bleeding is divided into three degrees: 1.
No bleeding; 2. 2: occasionally; 3: quite often.There are three degrees of prolapse: 1.
No prolapse; 2: occasionally; 3: quite often.NRS pain digital rating scale was adopted, that is, 0-10 was used to represent different degrees of pain, 0 was painless, and 10 was severe pain.
0 painless, 1-3 mild pain (pain does not affect sleep), 4-6 moderate pain, 7-9 severe pain (inability to fall asleep or waking up during sleep), 10 severe pain.
|
1st day, 1st week, 2nd week and 24th week
|
Failure rate
Time Frame: 1st day, 1st week, 2nd week and 24th week
|
Bleeding, prolapse, and anal pain remained the same after CAES.
Bleeding is divided into three degrees: 1.
No bleeding; 2. 2: occasionally; 3: quite often.There are three degrees of prolapse: 1.
No prolapse; 2: occasionally; 3: quite often.NRS pain digital rating scale was adopted, that is, 0-10 was used to represent different degrees of pain, 0 was painless, and 10 was severe pain.
0 painless, 1-3 mild pain (pain does not affect sleep), 4-6 moderate pain, 7-9 severe pain (inability to fall asleep or waking up during sleep), 10 severe pain.
|
1st day, 1st week, 2nd week and 24th week
|
Three-level EuroQol five dimensions (ED-5Q) health scale scores
Time Frame: 24th week
|
The ED-5Q questionnaire includes five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with three levels in each dimension (no/moderate/severe problem).
Through the Chinese time trade-off (TTO) value table, the health status of five dimensions will be converted into a preference weight of a ED-5Q index score for further analysis.
|
24th week
|
Adverse events (AEs)
Time Frame: 1st day, 1st week, 2nd week and 24th week
|
AEs refer to adverse medical events that occurs during or after CAES, including bleeding, anal pain, having difficulties in passing gas and defecation, infection, ulcer/bleeding in the injection points under endoscopic examination (5-7 days after CAES) and other symptoms.
|
1st day, 1st week, 2nd week and 24th week
|
severe adverse events (SAEs) severe adverse events (SAEs) severe adverse events (SAEs) Severe adverse events (SAEs)
Time Frame: 1st day, 1st week, 2nd week and 24th week
|
SAEs include serious complications directly or indirectly related to the CAES, such as death, bleeding, perforation, infection.
|
1st day, 1st week, 2nd week and 24th week
|
Participants' attitudes toward CAES
Time Frame: 24th week
|
The survey on the satisfaction with CAES efficacy, and the willingness to recommend CAES to others.
|
24th week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Faming Zhang, MD,PhD, The Second Hospital of Nanjing Medical University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhang T, Xu LJ, Xiang J, He Z, Peng ZY, Huang GM, Ji GZ, Zhang FM. Cap-assisted endoscopic sclerotherapy for hemorrhoids: Methods, feasibility and efficacy. World J Gastrointest Endosc. 2015 Dec 25;7(19):1334-40. doi: 10.4253/wjge.v7.i19.1334.
- Tomiki Y, Ono S, Aoki J, Takahashi R, Sakamoto K. Endoscopic sclerotherapy with aluminum potassium sulfate and tannic acid for internal hemorrhoids. Endoscopy. 2014;46 Suppl 1 UCTN:E114. doi: 10.1055/s-0034-1364884. Epub 2014 Mar 27. No abstract available.
- Tokunaga Y. Clinical utility of sclerotherapy with a new agent for treatment of rectal prolapse in patients with risks. J Clin Gastroenterol. 2014 Apr;48(4):356-9. doi: 10.1097/MCG.0b013e318299cab8.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
December 30, 2019
Primary Completion (Anticipated)
December 30, 2022
Study Completion (Anticipated)
June 30, 2023
Study Registration Dates
First Submitted
November 13, 2019
First Submitted That Met QC Criteria
November 16, 2019
First Posted (Actual)
November 19, 2019
Study Record Updates
Last Update Posted (Actual)
December 24, 2019
Last Update Submitted That Met QC Criteria
December 20, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAES-CN-191111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Prolapse
-
Mansoura UniversityCompletedComplete Rectal ProlapseEgypt
-
Marks Colorectal Surgical AssociatesUnknownInflammatory Bowel Diseases | Rectal Cancer | Diverticulitis | Colon Cancer | Colon Polyp | Rectal Polyp | Prolapse, RectalUnited States
-
Hospital de MataróCompletedHemorrhoids | Rectal Mucosa ProlapseSpain
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityCompletedRectal ProlapsePakistan
-
Al-Azhar UniversityCompleted
-
Weill Medical College of Cornell UniversityOlympusCompleted
-
University of Rome Tor VergataUnknown
-
Mansoura UniversityCompleted
-
KU LeuvenEnrolling by invitation
Clinical Trials on Cap-assisted endoscopic sclerotherapy
-
The Second Hospital of Nanjing Medical UniversityUnknownRectal Prolapse | Internal HemorrhoidChina
-
Chinese University of Hong KongCompletedColonoscopy | Lower Gastrointestinal TractChina
-
University of California, San DiegoCompleted
-
Renmin Hospital of Wuhan UniversityThe First Affiliated Hospital of Nanchang University; Zhejiang University; Hubei... and other collaboratorsNot yet recruitingHemorrhoids | Hemorrhoid Prolapse | Hemorrhoid | Hemorrhoid Bleeding | Hemorrhoid Pain | Hemorrhoids InternalChina
-
Indiana UniversityCompletedPolypsUnited States
-
The Catholic University of KoreaUnknown
-
Technical University of MunichCompletedDuodenal Papilla, MajorGermany
-
Technical University of MunichRotkreuzklinikum München gGmbH; Klinikum Freising; Klinikum Landshut-Achdorf; Städtisches... and other collaboratorsCompletedEndoscopic Diagnosis in EsophagusGermany
-
Dalin Tzu Chi General HospitalCompletedColonoscopy | Intubation Time | Cap-assisted ColonoscopyTaiwan
-
St John of God Hospital, ViennaCompleted